Self-administered Therapeutic Antibodies to 2020


Chart_Collage_160    Published December 2014  •  Catalog no. STA519F  •  Price US $3,850



The administration of therapeutic antibodies is becoming an increasingly important healthcare treatment method for a growing number diseases and indications having broad implications for patient health and well-being. To fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of antibody storage and administration. Population demographics and efforts by managed care providers to control healthcare costs are driving the growth in drug self-administration, particularly for chronic conditions, introducing a new class of naïve users to non-oral self-medication. This report analyzes eleven important therapeutic antibody segments and examines formulation, device and packaging factors, dosing frequency, and key regulatory, economic and competitive elements that represent risk factors and potential barriers to commercial success. Self-administered Therapeutic Antibodies to 2020 is a comprehensive analysis of this evolving sector.

Bar_GraphSelf-Administered Therapeutic Antibodies Report Prospectus (Download PDF)

Blue document Self-Administered Therapeutic Antibodies to 2020 Report Order Form (Download PDF)


Highlights

• Provides detailed analysis of approved therapeutic antibodies, their therapeutic markets, packaging and delivery strategies, and market presence
• Analyzes development-stage therapeutic antibodies, their therapeutic target/indication and development status, and device and delivery strategies
• Assesses current and future markets for therapeutic antibodies, and evaluates the market potential of therapeutic antibodies against established treatment regimens for each market segment
• Provides market data and forecasts to 2020
• Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
• Assesses the importance of pharma-device alliances and design partnerships on therapeutic antibody commercialization
• Evaluates the impact of economic, technology, and regulatory factors


Summary of Contents

Executive Summary

Antibody Therapeutics Market Dynamics

The Antibody Therapeutics Marketspace
The Challenge of Antibody Drug Delivery
Post-marketing Product Evolution
Clinical Trials and Drug Approvals
The Competitive Landscape
Demographics and Growth
Risks and Opportunities

Therapeutic Antibody Development Factors

Formulating Antibody Drugs
Formulation Strategies
Antibody Packaging & Delivery
Antibody Drug Distribution Strategies
Device Strategies for Injectable Antibodies
Device Options
Device Customization and Branding
DTC Marketing and Injectable Antibodies

Subcutaneous Injectable Therapeutic Antibodies

CD20
Rituximab (Rituxan – Europe)
IgE Inhibitor
Omalizumab (Zolair)
IL-12/IL-23 Inhibitor
Ustekinumab (Stelara)
IL-6 Inhibitor
Tocilizumab (Actemra)
Interleukin-1β Inhibitor
Canakinumab (Ilaris)
RANKL
Denosumab (Prolia)
TNF Inhibitor
Adalimumab (Humira)
Golimumab (Simponi)
Certolizumab (Cimzia)
Viral Epitopes
Palivizumab ((Synagis)

Approved Antibodies – From Infusion–to-Injection

α4 integrin
Vedolizumab (Entyvio)
Natalizumab (Tysabri – rrMS)
BLyS
Belimumab (Benlysta – HGS)
CD20
Rituximab (Rituxin)
Ofatumumab (Arzerra)
Endothelial Growth Factor Receptor Inhibitors
Bevacizumab (Avastin)
Epidermal Growth Factor Receptor Inhibitors
Trastuzumab (Herceptin)

Analysis/Assessment of Pipeline Antibodies being developed for SC Injection

CCR5
HIV
CD3/CD19
Acute Lymphocytic Leukemia
CD20
Autoimmunity
Thrombocytopenia
CD74
Lupus
CGRP
Migraine
FGF23
XLH
GM-CSF
Asthma
Arthritis
IL-4R
Dermatitis/Asthma
IL-5
COPD
IL-6R
Asthma
Arthritis
IL-13
Asthma
IL-17R
Psoriasis
IL-23
Psoriasis
LOXL2
Pancreatic Cancer
MASP-2
Thrombotic Microangiopathies
Pa Component
Cystic Fobrosis
PCSK9
LDL Reduction

Antibody Therapeutic Markets

Asthma
Autoimmunity
Infectious Disease
Oncology
Osteoporosis
Other Key Markets

Market Factors

Regional Regulations
Managed Care Initiatives
Patient Education and Compliance

Company Profiles